Drug Profile
GTX 201
Alternative Names: GTX-201Latest Information Update: 28 Feb 2022
Price :
$50
*
At a glance
- Originator Grace Therapeutics
- Developer Acasti Pharma
- Class Analgesics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Trigeminal neuralgia
Most Recent Events
- 28 Feb 2022 No recent reports of development identified for phase-I development in Trigeminal neuralgia in Unknown
- 27 Aug 2021 Grace Therapeutics has been acquired and merged into Acasti Pharma
- 31 Jan 2019 Grace Therapeutics pipeline, January 2019- update intro, KDM, phase, added HE